Nelfinavir induces TRAIL receptor upregulation in ovarian cancer cells

Biochemical and Biophysical Research Communications

Volumn 377, Issue 4, 2008, Pages 1309-1314

  Brüning, Ansgar ^a   Vogel, Marianne ^a   Burger, Petra ^a   Rahmeh, Martina ^a   Gingelmaier, Andrea ^a   Friese, Klaus ^a   Lenhard, Miriam ^a   Burges, Alexander ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Nelfinavir; Ovarian cancer; TRAIL

Indexed keywords

ANNEXIN; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; PROPIDIUM IODIDE; RECEPTOR ANTIBODY; SAQUINAVIR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

APOPTOSIS; ARTICLE; CANCER CELL; CELL VIABILITY; CONCENTRATION (PARAMETERS); DRUG EFFICACY; FIBROBLAST; HUMAN; HUMAN CELL; IMMUNE SYSTEM; IN VITRO STUDY; OVARY CANCER; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; FEMALE; HIV PROTEASE INHIBITORS; HUMANS; NELFINAVIR; OVARIAN NEOPLASMS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; UP-REGULATION;

EID: 56349084171     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2008.10.167     Document Type: Article

References (26)

1. Mitsuya H., Maeda K., Das D., and Ghosh A.K. Development of protease inhibitors and the fight with drug-resistant HIV-1 variants. Adv. Pharmacol. 56 (2008) 169-197
2. Cohen J. HIV drug shows promise as potential cancer treatment. Science 317 (2007) 1305
3. Schmidtke G., Holzhutter H.G., Bogyo M., Kairies N., Groll M., de Giuli R., Emch S., and Groettrup M. How an inhibitor of the HIV-I protease modulates proteasome activity. J. Biol. Chem. 274 (1999) 35734-35740
4. Gills J.J., Lopiccolo J., and Dennis P.A. Nelfinavir, a new anti-cancer drug with pleiotropic effects and many paths to autophagy. Autophagy 4 (2008) 107-109
5. Fraser M., Leung B., Jahani-Asl A., Yan X., Thompson W.E., and Tsang B.K. Chemoresistance in human ovarian cancer: the role of apoptotic regulators. Reprod. Biol. Endocrinol. 1 (2003) 66
6. Lage H., and Denkert C. Resistance to chemotherapy in ovarian carcinoma. Recent Results Cancer Res. 176 (2007) 51-60
7. Jin Z., and El-Deiry W.S. Overview of cell death signaling pathways. Cancer Biol. Ther. 4 (2005) 139-163
8. Dannenmann C., Shabani N., Friese K., Jeschke U., Mylonas I., and Brüning A. The metastasis-associated gene MTA1 is upregulated in advanced ovarian cancer, represses ERbeta, and enhances expression of oncogenic cytokine GRO. Cancer Biol. Ther. 11 (2008) 1462-1465
9. Runnebaum I.B., and Brüning A. Glucocorticoids inhibit cell death in ovarian cancer and up-regulate caspase inhibitor cIAP2. Clin. Cancer Res. 11 (2005) 6325-6332
10. Kendrick J.E., Estes J.M., Straughn Jr J.M., Alvarez R.D., and Buchsbaum D.J. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and its therapeutic potential in breast and gynecologic cancers. Gynecol. Oncol. 106 (2007) 614-622
11. Estes J.M., Oliver P.G., Straughn Jr. J.M., Zhou T., Wang W., Grizzle W.E., Alvarez R.D., Stockard C.R., LoBuglio A.F., and Buchsbaum D.J. Efficacy of anti-death receptor 5 (DR5) antibody (TRA-8) against primary human ovarian carcinoma using a novel ex vivo tissue slice model. Gynecol. Oncol. 105 (2007) 291-298
12. Kendrick J.E., Straughn Jr J.M., Oliver P.G., Wang W., Nan L., Grizzle W.E., Stockard C.R., Alvarez R.D., and Buchsbaum D.J. Anti-tumor activity of the TRA-8 anti-DR5 antibody in combination with cisplatin in an ex vivo human cervical cancer model. Gynecol. Oncol. 108 (2008) 591-597
13. Koschny R., Walczak H., and Ganten T.M. The promise of TRAIL-potential and risks of a novel anticancer therapy. J. Mol. Med. 85 (2007) 923-935
14. Koschny R., Ganten T.M., Sykora J., Haas T.L., Sprick M.R., Kolb A., Stremmel W., and Walczak H. TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancer-specific apoptosis within a therapeutic window. Hepatology 45 (2007) 649-658
15. Oliver P.G., LoBuglio A.F., Zinn K.R., Kim H., Nan L., Zhou T., Wang W., and Buchsbaum D.J. Treatment of human colon cancer xenografts with TRA-8 anti-death receptor 5 antibody alone or in combination with CPT-11. Clin. Cancer Res. 14 (2008) 2180-2189
16. Hotte S.J., Hirte H.W., Chen E.X., Siu L.L., Le L.H., Corey A., Iacobucci A., MacLean M., Lo L., Fox N.L., and Oza A.M. A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies. Clin. Cancer Res. 14 (2008) 3450-3455
17. Camidge D.R. Apomab: an agonist monoclonal antibody directed against Death Receptor 5/TRAIL-Receptor 2 for use in the treatment of solid tumors. Expert Opin. Biol. Ther. 8 (2008) 1167-1176
18. Saulle E., Petronelli A., Pasquini L., Petrucci E., Mariani G., Biffoni M., Ferretti G., Scambia G., Benedetti-Panici P., Cognetti F., Humphreys R., Peschle C., and Testa U. Proteasome inhibitors sensitize ovarian cancer cells to TRAIL induced apoptosis. Apoptosis 12 (2007) 635-655
19. Mariani S.M., and Krammer P.H. Surface expression of TRAIL/Apo-2 ligand in activated mouse T and B cells. Eur. J. Immunol. 28 (1998) 1492-1498
20. Vlahakis S.R., Bennett S.A., Whitehead S.N., and Badley A.D. HIV protease inhibitors modulate apoptosis signaling in vitro and in vivo. Apoptosis 12 (2007) 969-977
21. Rizza S.A., and Badley A.D. HIV protease inhibitors impact on apoptosis. Med. Chem. 4 (2008) 75-79
22. Hisatomi T., Nakazawa T., Noda K., Almulki L., Miyahara S., Nakao S., Ito Y., She H., Kohno R., Michaud N., Ishibashi T., Hafezi-Moghadam A., Badley A.D., Kroemer G., and Miller J.W. HIV protease inhibitors provide neuroprotection through inhibition of mitochondrial apoptosis in mice. J. Clin. Invest. 118 (2008) 2025-2038
23. López S., Miró O., Martínez E., Pedrol E., Rodríguez-Santiago B., Milinkovic A., Soler A., García-Viejo M.A., Nunes V., Casademont J., Gatell J.M., and Cardellach F. Mitochondrial effects of antiretroviral therapies in asymptomatic patients. Antivir. Ther. 9 (2004) 47-55
24. Miró O., Villarroya J., Garrabou G., López S., Rodríguez de la Concepción M., Pedrol E., Martínez E., Giralt M., Gatell J.M., Cardellach F., Casademont J., and Villarroya F. In vivo effects of highly active antiretroviral therapies containing the protease inhibitor nelfinavir on mitochondrially driven apoptosis. Antivir. Ther. 10 (2005) 945-951
25. Gills J.J., Lopiccolo J., Tsurutani J., Shoemaker R.H., Best C.J., Abu-Asab M.S., Borojerdi J., Warfel N.A., Gardner E.R., Danish M., Hollander M.C., Kawabata S., Tsokos M., Figg W.D., Steeg P.S., Dennis P.A., and Nelfinavir. A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo. Clin. Cancer Res. 13 (2007) 5183-5194
26. Brunner T.B., Geiger M., Grabenbauer G.G., Lang-Welzenbach M., Mantoni T.S., Cavallaro A., Sauer R., Hohenberger W., and McKenna W.G. Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer. J. Clin. Oncol. 26 (2008) 2699-2706